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proteinuria induces a proinflammatory injury in tubular
cells, which can ease the development of interstitial fibrosis
and tubular atrophy.3 However, at variance with type I
diabetic patients, a considerable number of type II diabetic
patients, even with microalbuminuria or macroalbumin-
uria, have normal glomerular structure but show tubulo-
interstitial and/or arteriolar abnormalities.4 In type II
diabetes, hyperglycemia5 and hypertension6 may cooperate
to impair the physiologic mechanism that main-
tains normal glomerular capillary pressure and tubular
function.6,7
In our study, we evaluated apoptosis in renal biopsies
obtained from patients with early or advanced type II
diabetic nephropathy. We found that apoptotic changes
are diffusely increased in glomeruli, tubuli, and vascular
endothelia. According to our findings, apoptotic cell loss
is already observed in proteinuric patients with normal
or subnormal glomerular filtration rate and only modest
biopsy changes, suggesting that the acceleration of
apoptotic processes is an early phenomenon, Thus, besides
being a pathogenic mechanism of cell loss, apoptosis
can also be an additional tool for the evaluation of early
kidney damage. In patients with more advanced disease,
glomerular apoptosis is directly related to the histological
scores of glomerular sclerosis, mesangial proliferation, and
tubule atrophy.
Low serum magnesium level is an independent pre-
dictor of incident type II diabetes.8 In addition, hypo-
magnesemia has been linked to poor glycemic control and
diabetes complication.9 We did not study kidney magne-
sium handling in our patients. However, the observation
by Futrakul is interesting, as the increased incidence
of hypomagnesemia among patients with type II diabetes
has so far been considered multifactorial.9 We agree with
their suggestions in studying the function of kidney tubule
in patients with type II diabetes mellitus, as a clue for
the occurrence of early microvascular damage. Further
exploration of both the biology of renal cells and the
mechanisms of diabetic disease will be critical for
developing new preventive, diagnostic and therapeutic
approaches to diabetic nephropathy.
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To the Editor: I sincerely congratulate Fervenza et al.1
on their paper describing the effect of rituximab in idiopathic
membranous nephropathy. In fact, I believe that their results
might allow for a more optimistic assessment. Plotting from
their Table 2, the proteinuria over the time from 6 months
before treatment and until 12 months after treatment very
clearly shows that nothing happens under the 6-month
observation, but a clear course then develops afterward that
does not end at 12 months. To show that, it is helpful to use a
log-transformed proteinuria. Figure 1 indicates that the
chosen method of analysis, a paired t-test based on the
baseline to 12 months difference, is conservative and uses less
information than is, in fact, available.
To analyze the figure, a linear mixed model,2 with
intercepts and slopes modeled (‘random’), was made from
the reported data using the freely available R.3 It was found
that both time (t¼3.45, P¼ 0.0008) and creatinine
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Figure 1 | Longitudinal effect of Rituximab on proteinuria
(log transformed).
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clearance (t¼3.09, P¼ 0.003) significantly affected the
course of log(proteinuria) (and also proteinuria per se), when
using a comprehensive model. This is in contrast to merely
subjecting the variables to t-tests comparing responders and
nonresponders at two time points. Retreatment, age, stage,
disease duration, and sex were also of minor importance in
the comprehensive model.
Compared to other diseases with surmised immune
pathophysiology, the longevity of the response to rituximab
in membranous nephropathy is amazing. We look forward
to use rituximab to probe into the elusive pathophysiology
of membranous nephropathy. Perhaps optimally analyzed
studies, such as the present study, including urine proteomics
to pinpoint the immune pathophysiology will be feasible
and informative, and supplement conventional, controlled
trials.
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We appreciate Dr Ring’s1 interest in our paper. His
reanalysis using mixed models resulted in a conclusion
similar to our stated results that urine protein decreased
significantly over time for some patients on rituximab.
Further, he found a significant association between base-
line creatinine clearance and urine protein response (when
treated as a quantitative factor). We agree that longitudinal
mixed models are generally more efficient in this setting.
Our small phase 2 trial did not utilize such analyses for
two reasons. One, our analysis was focused on the primary
end point as given in the protocol; 12-month change in
urine protein compared with baseline. This end point was
partly driven by the well-known variations in the natural
history of membranous nephropathy and our feeling that
a treatment effect must endure for at least 12 months to
be considered potentially effective. Protein reductions in
the early post-treatment period followed by increases
(relapses) in later months could result in significant change
in mean slopes for proteinuria but minimal absolute
change at 12 months relative to baseline. The protocol
did include within-patient slopes (using all visits) as a
secondary end point. This analysis (similar in principle to
the mixed models approach) resulted in significant protein
slopes, and the same conclusion was obtained using the
12-month change data, and, as such, it was not included
in the paper. Second, to produce reliable regression
models, it is generally advisable to have at least 10 patients
per predictor variable.2 With only 15 subjects, we felt the
data set was too small to perform comprehensive modeling
with more than one predictor.
We agree with Dr Ring’s observation that prolonged
follow-up is necessary to see the full effect of rituximab
on proteinuria. This may not be unique to rituximab in
this disease. In the trial by Ponticelli et al.3 of methyl-
prednisolone and chlorambucil in membranous nephro-
pathy, few complete remissions occurred during the
6-month treatment phase and almost half occurred at
more than 12 months.
Why some patients respond to rituximab whereas
others do not remains a key question. We agree entirely
with Dr Ring’s statement that this type of study should be
designed and methods used in the analyses should focus
not only on demonstrating potential efficacy but also on
maximizing the information derived by including investi-
gations that may help define the immune pathophysiology
of membranous nephropathy. We are trying to address this
with an ongoing study of rituximab in patients with
membranous nephropathy (http://www.clinicaltrials.gov).
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